Mesothelioma Cancer Centers
Moffitt Cancer Center
Doctors Affiliated with this Treatment Facility
Founded in 1986, the H. Lee Moffitt Cancer Center & Research Institute is a nonprofit cancer treatment center located on the Tampa campus of the University of South Florida. It is the primary cancer treatment center affiliated with the University of South Florida College of Medicine. Moffitt, a National Cancer Institute Comprehensive Cancer Center, offers 13 specially designed clinical programs for the treatment of various types of cancers.
The Moffitt Cancer Center is named after H. Lee Moffitt, a former Florida state representative and cancer survivor who in 1978 started pushing to bring a cancer center to the Tampa area. At the time, statistics showed that more than 14,000 new cancer cases were expected each year within a 100-mile radius of Tampa. Moffitt was shocked by these numbers, and worked with University of South Florida College of Medicine Dean Andor Szentivanyi to get the community and state legislature on board with the new cancer center. After eight years of work, the 162-bed, $70 million cancer center was dedicated in October 1986. It was named after Moffitt, who by then was serving as Speaker of the Florida State of Representatives.
In 1990, the Moffitt Cancer Center acquired a nearby Research Center building, which allowed the facility to put more emphasis on research activities. Researchers at the new center aimed to make medical advances that could very quickly be utilized with patients. After receiving $12 million in funding from the state of Florida, the 100,000-square-foot Moffitt Research Center opened its doors in 1995. Expansions in 1999 and 2003 nearly doubled the research center’s size and allowed it to greatly expand its operations.
The H. Lee Moffitt Cancer Center’s mission is to contribute to the prevention and cure of cancer, and also “to be a leader in scientific discovery and translation into compassionate care, cures, and prevention of cancer for our community and the world.” That is, the cancer center seeks to be at the forefront of curing cancer and also utilizing that research at the patient’s bedside.
Today, the Moffitt Cancer Center is dedicated to treating and researching a variety of cancers, including malignant mesothelioma. They have a dedicated Mesothelioma Treatment and Research Center that diagnoses and treats all types of mesothelioma, including pleural, peritoneal and pericardial mesothelioma.
The Mesothelioma Treatment and Research team uses a multidisciplinary approach, pulling members of all prominent departments to create tailored treatment plans for the patient’s specific situation. Treatments often include surgery, chemotherapy and radiation therapy, but Moffitt Cancer Center also utilizes novel treatment types like immunotherapy, cancer vaccines and other emerging treatment options.
Patients do not need a referral to seek care from the Mesothelioma Treatment and Research Center, so all patients are able to explore their options for treatment and potentially engage in specialized mesothelioma clinical trials.
- Experimental treatments
- Mesothelioma vaccines
- Pericardial mesothelioma
- Peritoneal mesothelioma
- Pleural mesothelioma
- Radiation therapy
- National Cancer Institute (NCI) designation
- National Comprehensive Cancer Network member
Mesothelioma Clinical Trials at Moffitt Cancer Center
The following clinical trials are in progress or actively recruiting participants at Moffitt Cancer Center:
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma Last Updated: July 18, 2019 Status: Recruiting
Conditions: Mesothelioma, Malignant Last Updated: July 10, 2019 Status: Recruiting
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Conditions: Mesothelioma Last Updated: October 9, 2018 Status: Recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
Moffitt Cancer Center. Mesothelioma Treatment Information.